Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Author:
Craig L Leonardi,Alexa B Kimball,Kim A Papp,Newman Yeilding,Cynthia Guzzo,Yuhua Wang,Shu Li,Lisa T Dooley,Kenneth B Gordon
Copyright © 2008 Elsevier Ltd. All rights reserved.